US pharma Acadia buys Polish drug rights

US pharmaceutical company Acadia has purchased the exclusive rights to the development of a new neuropsychiatric drug from the Polish company Adamed in a deal worth above PLN 470 million (EUR 102m). Adamed has carried out the transaction at an early stage of research, the Puls Biznesu economic newspaper reported. "We are granting an exclusive licence for the further development of the drug," the newspaper was told by Bartlomiej Zerek, Innovation Department director at Adamed.